Recruiting studies: Human Papillomavirus Negative Neck Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 · 3 location(s) · Mayo Clinic · NCT05541016 Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
Phase 2 · 1 location(s) · Medical University of South Carolina · NCT07513389 Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcino
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161545 Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squ
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06448026 Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and
Phase 1 · 1 location(s) · Mayo Clinic · NCT06997094 Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT04220749 Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC
Phase 2 · 1 location(s) · Gruppo Oncologico del Nord-Ovest · NCT04681469 Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06935188 Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
Phase 1 · 1 location(s) · University of Chicago · NCT06005324 Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734 Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers
Phase N/A · 2 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT07512921 A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative He
Phase 3 · 112 location(s) · AVEO Pharmaceuticals, Inc. · NCT06064877

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.